CG
ADPT icon

Cutler Group’s Adaptive Biotechnologies ADPT Stock Holding History

Cutler Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-800
Closed -$6K – 4835
2022
Q2 		$6K Sell
800
-1,000
-56% -$8.79K ﹤0.01% 3539
2022
Q1 		$24K Buy
1,800
+1,100
+157% +$17.3K ﹤0.01% 2879
2021
Q4 		$19K Hold
700
– – ﹤0.01% 3149
2021
Q3 		$23K Hold
700
– – ﹤0.01% 3207
2021
Q2 		$28K Buy
+700
New +$27.2K ﹤0.01% 2996
2020
Q2 		– Sell
-300
Closed -$10.9K – 4295
2020
Q1 		$8K Buy
300
+100
+50% +$2.79K ﹤0.01% 2808
2019
Q4 		$5K Sell
200
-545
-73% -$15.7K ﹤0.01% 3005
2019
Q3 		$23K Buy
+745
New +$30.4K ﹤0.01% 2076

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's ADPT Position: Q3 2022 in Review

Cutler Group sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 800 shares — an estimated $6K sold.

Cutler Group first reported a position in ADPT in Q3 2019 and held it in 8 quarters. The position peaked at $28K in Q2 2021. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

  • Cutler Group reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 800 Adaptive Biotechnologies shares in Q3 2022, an estimated $6K.
  • Cutler Group first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 8 quarters.
  • Cutler Group's Adaptive Biotechnologies position peaked at $28K in Q2 2021.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.